Literature DB >> 8049457

Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry.

Z Bebök1, B Márkus, P Németh.   

Abstract

The function of different growth factors in the development and progression of malignant tumors and the role of cytotoxic cytokines in the host response generated against neoplasms have been recently studied. Anti-TGF-alpha and anti-TNF-alpha monoclonal antibody families have been developed and characterized previously by our laboratory. Libraries of anti-TGF-alpha and anti-TNF-alpha monoclonal antibodies were selected for equal immunoreactivity both in native (frozen) and in formaldehyde fixed, paraffin embedded histological sections. No differences were found between native and fixed samples demonstrated in 10 cases in the present prospective study. Retrospective investigation was performed in 35 histopathological specimens of breast cancer patients detailed clinically and observed during 5 years after the surgical treatment. Correlation between TGF-alpha and/or TNF-alpha expression and clinical staging--TNM score, lymph node metastasis, tumor recurrence and survival time--was analyzed. According to our present study, the TGF-alpha positive patients had worse clinical prognosis than the TNF-alpha positive and double positive cases during long term observation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049457     DOI: 10.1007/bf00666476

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

Authors:  A A Jakubowski; E S Casper; J L Gabrilove; M A Templeton; S A Sherwin; H F Oettgen
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

Review 2.  Transforming growth factor-alpha: structure and biological activities.

Authors:  R Derynck
Journal:  J Cell Biochem       Date:  1986       Impact factor: 4.429

3.  Endogenous tumour necrosis factor in cancer patients.

Authors:  P J Selby; S Hobbs; C Viner; E Jackson; I E Smith; T J McElwain
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

Review 4.  Oncogenes and growth factors.

Authors:  J G Sinkovics
Journal:  Crit Rev Immunol       Date:  1988       Impact factor: 2.214

5.  Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro.

Authors:  K Morishige; H Kurachi; K Amemiya; H Adachi; M Inoue; A Miyake; O Tanizawa; Y Sakoyama
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

Review 6.  Autocrine and paracrine growth regulation of breast cancer: clinical implications.

Authors:  C K Osborne; C L Arteaga
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

7.  Recombinant human tumor necrosis factor--II. Antitumor effect on murine and human tumors transplanted in mice.

Authors:  Y Sohmura; K Nakata; H Yoshida; S Kashimoto; Y Matsui; H Furuichi
Journal:  Int J Immunopharmacol       Date:  1986

8.  Tumor necrosis factor in children with malignancies.

Authors:  U M Saarinen; E K Koskelo; A M Teppo; M A Siimes
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

9.  Tumor necrosis factor increases the number of epidermal growth factor receptors on human fibroblasts.

Authors:  V J Palombella; D J Yamashiro; F R Maxfield; S J Decker; J Vilcek
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

10.  Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status.

Authors:  Y Umekita; N Enokizono; Y Sagara; K Kuriwaki; T Takasaki; A Yoshida; H Yoshida
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992
View more
  5 in total

1.  Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.

Authors:  L Molnár; T Berki; A Hussain; P Németh; H Losonczy
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  MicroRNA-374b inhibits breast cancer progression through regulating CCND1 and TGFA genes.

Authors:  Yan Liu; Ai Zhang; Ping-Ping Bao; Li Lin; Yina Wang; Haijian Wu; Xiao-Ou Shu; Aiguo Liu; Qiuyin Cai
Journal:  Carcinogenesis       Date:  2021-04-30       Impact factor: 4.944

3.  Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Authors:  James W Antoon; Rongye Lai; Amanda P Struckhoff; Ashley M Nitschke; Steven Elliott; Elizabeth C Martin; Lyndsay V Rhodes; Nam Seung Yoon; Virgilio A Salvo; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  Sci Rep       Date:  2012-07-27       Impact factor: 4.379

4.  Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.

Authors:  R D Leek; R Landers; S B Fox; F Ng; A L Harris; C E Lewis
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

5.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

Authors:  M E Harper; E Glynne-Jones; L Goddard; V J Thurston; K Griffiths
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.